Previous Close | 28.50 |
Open | 28.43 |
Bid | 28.24 x 200000 |
Ask | 28.43 x 200000 |
Day's Range | 28.43 - 28.43 |
52 Week Range | 17.45 - 38.80 |
Volume | |
Avg. Volume | 0 |
Market Cap | 1.404B |
Beta (5Y Monthly) | 1.75 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.23 |
Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 65.04 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATQP.F
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High End of Guidance Range, with Fourth Quarter Revenue Growth of Approximately 24% MACI Arthroscopic Commercial Launch Now Planned for 2024 CAMBRIDGE, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results for the fou